Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression

✍ Scribed by Masaru Mitsui; Makiya Nishikawa; Lei Zang; Mitsuru Ando; Kayoko Hattori; Yuki Takahashi; Yoshihiko Watanabe; Yoshinobu Takakura

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 229 KB
• Volume: 11
• Category: Article
• ISSN: 1099-498X
• DOI: 10.1002/jgm.1317

✦ Synopsis

Abstract

Background

Nonviral gene transfer generally suffers from short‐term expression of transgenes. We have previously demonstrated that plasmids with reduced CpG content exhibited a more prolonged expression of murine interferon (IFN)‐β or IFN‐γ, which was effective in inhibiting metastatic tumor growth. A further extension of the duration of transgene expression could be achieved by controlling the number and location of CpG motifs in plasmid DNA.

Methods

Luciferase‐expressing plasmids with differing CpG content were injected into the tail vein of mice by the hydrodynamic injection method. The effects of CpG content on the duration of transgene expression were examined, focusing on cytosine methylation and pro‐inflammatory cytokines. Based on the findings, IFN‐γ‐expressing plasmids were constructed and their transgene expression and inhibitory effect on pulmonary metastasis were evaluated.

Results

Plasmids with a few CpG motifs showed a prolonged luciferase activity in the liver. Methylation of CpG motifs in plasmids reduced the expression and the extent of this reduction was greater for plasmids with a high CpG content. Pro‐inflammatory cytokines hardly affected the expression. pCpG‐Muγ, the IFN‐γ‐expressing plasmid, which contains 20 CpG motifs only in the cDNA region, exhibited a sustained IFN‐γ concentration at therapeutic levels, and had a great inhibitory effect on the pulmonary metastasis of tumor cells.

Conclusions

The duration of transgene expression of IFN‐γ was successfully increased by reducing the CpG content of IFN‐expressing plasmid vector, which resulted in an increased anticancer activity of IFN gene transfer. Copyright © 2009 John Wiley & Sons, Ltd.